Navigation Links
Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
Date:9/13/2007

netic testing in sport and exercise also raise some ethical concerns, for example in identifying potential athletic ability before birth.

An Australian company already offers the first genetic performance test (for the ACTN3 gene) which has been linked to sprint and power performance.

The report authors are sceptical about whether this test is useful but anticipate that more advanced versions of these tests will be available in future.

We are not yet at a point where we can identify a potential future Olympic champion from genetic tests but we may not be very far away, said Dr Williams, who wrote the report with Drs Henning Wackerhage (Aberdeen University), Andy Miah (University of Paisley), Roger Harris (University of Chichester) and Hugh Montgomery (University College London).

They highlight two dangers of genetic performance tests. Firstly, genetic performance tests might later be linked to disease. For example, a muscle growth gene may later be linked to cancer growth.

Not all people may want to know, while young that they are at increased risk of cancer by early middle age, but they might inadvertently become aware of that just because they had a sport gene test, said Dr Williams.

Secondly, genetic performance tests can be performed even before birth and this may lead to the selection of foetuses or to abortions based on athletic potential.

The report recommends genetic counselling and that the testing should be confined to mature individuals who fully understand the relevant issues.

Genetic tests might also be used to screen for health risks during sport such as genes that are linked to sudden cardiac death.

Genetic tests for sudden cardiac death are already available but the report recommends that such testing should not be enforced on athletes.

Problems with mandatory testing are highlighted by the case of the basketball player Eddy Curry, who had an irregular he
'/>"/>

Contact: Andrew McLaughlin
a.mclaughlin@bath.ac.uk
44-012-253-86883
University of Bath
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Nobel Prize for Medicine shared by Three scientists
2. Scientists plan human cloning clinic in the United States
3. Scientists crack mechanism of Leptin-Obesity Hormone
4. Scientists use plant hormones to fight cancer
5. American scientists alter gene makeup of babies
6. Expose on eating disorders!! Scientists trace “brain’s eating control center pathway”
7. Scientists found ancient Human Germ Killer
8. Scientists locate key hormone involved in appetite control
9. Scientists open the book of life
10. Electronic nose by Italian scientists
11. Scientists review SARS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2008)...-five day OnBase deployment critical in electronic...efit patients, CLEVELAND, July 9 /PRNewswire/ -- ...rise document management software suite, announced...sults since the deployment of,OnBase in March. Bas... four,states, SSM is a forward-thinking health car...
(Date:7/9/2008)...NTO, July 9 /PRNewswire-FirstCall/ - MDS Inc. (TSX...and services to the global life,sciences markets, ...f,Canada Limited (AECL) with notice of arbitration...el AECL to fulfill its contractual obligations,und... (ILTSA) and if not,granted, seeking significant m...
(Date:7/9/2008)... DRE, Inc., a premier internation...s its customers that as much as $250,000 in medica...come tax filings. , Louis...mulus Act of 2008, in accordance with Tax Code Sec...al equipment bought in 2008. This could make 2008 ...
(Date:7/9/2008)... InsuranceSpecialists.com, a lead...or almost a decade, now offers comprehensive infor...idential candidates are taking on health reform as...ment-free, supplies unbiased material on medical, ...elp consumers make the best choices in coverage fo...
Breaking Medicine News(10 mins):Health News:SSM Health Care Upgrades Patient Care With Speedy Document Management Implementation 2Health News:SSM Health Care Upgrades Patient Care With Speedy Document Management Implementation 3Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 2Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 3Health News:Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 2Health News:InsuranceSpecialists.com Looks at the Candidates and Health Reform 2Health News:InsuranceSpecialists.com Looks at the Candidates and Health Reform 3
...cay has been developed by BASF, a German company, ...The company claims its// product can reduce the am... The product was developed in collaboration with ... The gum helps in fighting tooth decay by prevent...
...s and soft drinks in hospitals, schools and other ...betes and obesity. Australia// has the world's fa...is strongly linked with type-2 diabetes. In an ar... Journal of Australia, Paul Zimmet, Director of th...
...eens' attitudes that covers an overall picture of ...immoral practices, one// third of the American tee...gal drugs were used while their parents were at ho...e aware of what was happening when teenagers parti...
... breast cancer test, which could save several wome...ady, doctors have been using core needle biopsy to...ination. This new test involves the study of gen...s may help in detecting more aggressive cancers th...
Other Medicine News:Health News:Parents ignorant about kids' immoral practices 2Health News:Novel test for diagnosis of breast cancer 2
(Date:7/6/2008)...rketing Authorization Application currently ...E, July 7 /- Cell Therapeut...ced the publication of results from its,randomized...poliglumex,CT-2103) with gemcitabine or vinorelbi...) patients with previously untreated non-small cel...
(Date:7/3/2008)...ewswire-USNewswire/ -- All newborn infants,should ...esent at birth,according to a new recommendation ...recommendation and the accompanying summary of evi...Children whose hearing is impaired at birth, durin...with verbal and nonverbal communication and,social...
(Date:7/3/2008)...MBRIDGE Massachusetts, July 3,/PRNewswire-FirstCal...ology company, Jerini AG for an equity purchase p...a (HAE) product, FIRAZYR(R), to its Human Genetic... global sales expected to be around $350-400 mill...ve environment, - Expected to be accretive for No...
(Date:7/2/2008)...y Endpoint Met in Stage 1 of Two-Stage Study ...ble Patients to Date Continue to Show Objective Tu...e -, TUSTIN, Calif., July 2 /PRNewswire-FirstCall...M ) today reported that its lead product,candidate...imary endpoint,in its ongoing Phase II clinical tr...
Breaking Medicine Technology:Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Task Force Recommends Screening for Hearing Loss in All Newborns 2Task Force Recommends Screening for Hearing Loss in All Newborns 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 2Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 4Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 5Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 6Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 7Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 8Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 2Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 3Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 4CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 1CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 2CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 3International study strengthens case for daily calcium pill 195 1International study strengthens case for daily calcium pill 195 2Methamphetamine study suggests increased risk for HIV transmission 192 1Methamphetamine study suggests increased risk for HIV transmission 192 2Embryonic Stem Cells Repair Human Heart 190 1Embryonic Stem Cells Repair Human Heart 190 2Embryonic Stem Cells Repair Human Heart 190 3
...Presented at Society of Nuclear,Medicine Annual Me...stCall/ --,Immunomedics, Inc. , a biopharmaceutica...ies to treat cancer and other serious,diseases, to...en,(CEA) antibody, labetuzumab, labeled with the r...active when given in two doses,to patients with co...
...omide in Multiple Myeloma,Presented at the America..., CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ --...ults of a Phase III study,demonstrating that the a...s overall survival (OS) by 17.6 months in patients...eloma compared to the,current standard of care. Th...
Other Medicine Technology:Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 2Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 3Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 4Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 5Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 6
The ProtecPoint Exit Alerting System, instantly help protect individuals (e.g. patients, staff) and assets (e.g. medical equipment), with easily-mountable exit controllers placed throughout your faci
...nt of controlled substances, critical supplies, or...vess" are designed to perform this function. Conti...ervention. Radio frequency identification (RFID) t...lf™ product solutions incorporate custom desi...
Agility can facilitate bed and room management through business process optimization using RFID technology. Bed and room management may be integrated with other AgileTrac products.
Assetrac allows identification, location, and protection of your assets.
Medicine Products: